Unknown

Dataset Information

0

AZD3463, an IGF-1R inhibitor, suppresses breast cancer metastasis to bone via modulation of the PI3K-Akt pathway.


ABSTRACT: Background:The bone-derived insulin-like growth factor I (IGF-1) and its receptor IGF-1R play a crucial role in promoting the survival and proliferation of cancer cells, and have thus been considered as prime targets for the development of novel antitumor therapeutics. Methods:By using the MDA-MB-231BO cell line, which is the osteotropic metastatic variant of the human breast adenocarcinoma cell line MDA-MB-231, and an in vivo model of breast cancer metastasis to bone, the current study evaluated the effect of AZD3463, an IGF-1R inhibitor, used alone or in combination with zoledronic acid (ZA), on the regulation of IGF-1R associated signal pathway and treatment of bone metastases (BM). Cell proliferation and invasion were measured by methyl thiazolyl tetrazolium (MTT) and Transwell assay respectively. Apoptotic cell number was detected by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL). Results:AZD3463 was shown to alleviate IGF-1R phosphorylation promoted by IGF-1 treatment in MDA-MB-231BO cells in a dose-dependent manner. In both the cells and the mouse model, 5 nM of AZD3463 stimulated cell apoptosis and suppressed proliferation on a level similar to that of 100 µM of ZA. Remarkably, the combined use of AZD3463 and ZA exhibited a synergistic effect and greater antitumor activity compared to when they were employed individually. Mechanistic investigations indicated that the apoptosis-inducing activity of AZD3463 could be associated to its role in the activation of the phosphoinositide 3-kinase (PI3K)-Akt signaling pathway. Conclusions:These findings suggested that AZD3463 could serve as a promising therapeutic molecule for treating BM in breast cancer patients, particularly when applied in conjunction with ZA or other antitumor agents.

SUBMITTER: Hu GF 

PROVIDER: S-EPMC7186597 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

AZD3463, an IGF-1R inhibitor, suppresses breast cancer metastasis to bone via modulation of the PI3K-Akt pathway.

Hu Guang-Fu GF   Wang Cheng C   Hu Guang-Xia GX   Wu Ge G   Zhang Chengjiao C   Zhu Wei W   Chen Cong C   Gu Yutong Y   Zhang Hongwei H   Yang Zi'ang Z  

Annals of translational medicine 20200301 6


<h4>Background</h4>The bone-derived insulin-like growth factor I (IGF-1) and its receptor IGF-1R play a crucial role in promoting the survival and proliferation of cancer cells, and have thus been considered as prime targets for the development of novel antitumor therapeutics.<h4>Methods</h4>By using the MDA-MB-231BO cell line, which is the osteotropic metastatic variant of the human breast adenocarcinoma cell line MDA-MB-231, and an <i>in vivo</i> model of breast cancer metastasis to bone, the  ...[more]

Similar Datasets

| S-EPMC10607899 | biostudies-literature
| S-EPMC5354845 | biostudies-literature
| S-EPMC5053668 | biostudies-literature
| S-EPMC4395227 | biostudies-literature
| S-EPMC11294307 | biostudies-literature
| S-EPMC6653615 | biostudies-literature
| S-EPMC4767476 | biostudies-literature
| S-EPMC8531461 | biostudies-literature
| S-EPMC10860326 | biostudies-literature
| S-EPMC10067542 | biostudies-literature